The use of fidaxomicin for treatment of relapsed clostridium difficile infections in patients with cancer

Pharmacotherapy

Volumn 34, Issue 11, 2014, Pages 1220-1225

  Esmaily Fard, Amin ^a   Tverdek, Frank P ^a   Crowther, David M ^a   Ghantoji, Shashank S ^a   Adachi, Javier A ^a   Chemaly, Roy F ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

cancer; Clostridium difficile; fidaxomicin; infection; recurrence

Indexed keywords

FIDAXOMICIN; METRONIDAZOLE; VANCOMYCIN; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT;

ADULT; AGED; ARTICLE; BACTERIUM IDENTIFICATION; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; GRAFT VERSUS HOST REACTION; HUMAN; LEUKEMIA; LYMPHOMA; MALE; MALIGNANT NEOPLASTIC DISEASE; MIDDLE AGED; OUTCOME ASSESSMENT; RECURRENT DISEASE; RELAPSE; RETROSPECTIVE STUDY; TREATMENT FAILURE; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; VERY ELDERLY; YOUNG ADULT; CANCER CENTER; COMPLICATION; DRUG EFFECTS; ELECTRONIC MEDICAL RECORD; ENTEROCOLITIS, PSEUDOMEMBRANOUS; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; MICROBIOLOGY; MULTIDRUG RESISTANCE; NEOPLASM; PATHOGENICITY; PEPTOCLOSTRIDIUM DIFFICILE; PRESCRIPTION; PUBLICATION; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CANCER CARE FACILITIES; CLOSTRIDIUM DIFFICILE; DRUG PRESCRIPTIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ELECTRONIC HEALTH RECORDS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; FORMULARIES, HOSPITAL; HUMANS; IMMUNOCOMPROMISED HOST; MALE; MIDDLE AGED; NEOPLASMS; RECURRENCE; RETROSPECTIVE STUDIES; TEXAS; YOUNG ADULT;

EID: 84908874822     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1479     Document Type: Article

References (10)

1. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31: 431-55.
2. Khan A, Raza S, Batul SA, et al. The evolution of Clostridium difficile infection in cancer patients: epidemiology, pathophysiology, and guidelines for prevention and management. Recent Pat Antiinfect Drug Discov 2012; 7: 157-70.
3. Cornely OA, Miller MA, Fantin B, et al. Resolution of Clostridium difficile-associated diarrhea in patients with cancer treated with fidaxomicin or vancomycin. J Clin Oncol 2013; 31: 2493-9.
4. Optimer Pharmaceuticals, Inc. Dificid (fidaxomicin) package insert. San Diego, CA; 2013.
5. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364: 422-31.
6. Mullane KM, Miller MA, Weiss K, et al. Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin Infect Dis 2011; 53: 440-7.
7. Kamboj M, Son C, Cantu S, et al. Hospital-onset Clostridium difficile infection rates in persons with cancer or hematopoietic stem cell transplant: a C3IC network report. Infect Control Hosp Epidemiol 2012; 33: 1162-5.
8. McFarland LV, Elmer GW, Surawicz CM,. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002; 97: 1769-75.
9. Johnson S, Schriever C, Galang M, et al. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis 2007; 44: 846-8.
10. Johnson S, Schriever C, Patel U, et al. Rifaximin redux: treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment. Anaerobe 2009; 15: 290-1.